Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model

Arthritis and Rheumatism

Volumn 56, Issue 4, 2007, Pages 1219-1233

  Yang, Jun Qi ^a   Wen, Xiangshu ^b   Liu, Hongzhu ^a   Folayan, Gbolahan ^b   Dong, Xin ^b   Zhou, Min ^b   Van Kaer, Luc ^c   Singh, Ram Raj ^b,d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CD3 ANTIBODY; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PBS 57; T LYMPHOCYTE RECEPTOR; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; GENETIC SUSCEPTIBILITY; GENOTYPE; GERM LINE; KNOCKOUT MOUSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN CELL; THYMOCYTE;

ANIMALS; ANTIGENS, CD1; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; INTERFERON TYPE II; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; MICE, KNOCKOUT; SPLEEN; T-LYMPHOCYTES; THYMUS GLAND;

EID: 34247216264     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22490     Document Type: Article

References (63)

1. Singh RR. SLE: translating lessons from model systems to human disease. Trends Immunol 2005;26:572-9.
2. Shivakumar S, Tsokos GC, Datta SK. T cell receptor α/β expressing double-negative (CD4-/-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12.
3. Singh RR, Kumar V, Ebling FM, Southwood S, Sette A, Sercarz EE, et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 1995;181:2017-27.
4. Peng SL, Madaio MP, Hayday AC, Craft J. Propagation and regulation of systemic autoimmunity by γδ T cells. J Immunol 1996;157:5689-98.
5. Singh RR, Ebling FM, Albuquerque DA, Saxena V, Kumar V, Giannini EH, et al. Induction of autoantibody production is limited in nonautoimmune mice. J Immunol 2002;169:587-94.
6. H-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med 2002;196:731-41.
7. β gene family. Nature 1987;329:251-4.
8. Yankelevich B, Knobloch C, Nowicki M, Dennert G. A novel cell type responsible for marrow graft rejection in mice: T cells with NK phenotype cause acute rejection of marrow grafts. J Immunol 1989;142:3423-30.
9. Sykes M. Unusual T cell populations in adult murine bone marrow: prevalence of CD3+CD4-CD8- and αβ TCR+NK1.1+ cells. J Immunol 1990;145:3209-15.
10. Ballas ZK, Rasmussen W. NK1.1+ thymocytes: adult murine CD4-, CD8- thymocytes contain an NK1.1+, CD3+ , CD5hi, CD44hi, TCR-V/β8+ subset. J Immunol 1990;145:1039-45.
11. Bendelac A, Schwartz RH. CD4+ and CD8+ T cells acquire specific lymphokine secretion potentials during thymic maturation. Nature 1991;353:68-71.
12. Arase H, Arase N, Nakagawa K, Good RA, Onoe K. NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol 1993;23:307-10.
13. pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285-95.
14. β family. Proc Natl Acad Sci U S A 1992;89:6506-10.
15. - T cells in mice and humans. J Exp Med 1994;180:1097-106.
16. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant Vα14+ TCR α chain in NK1.1+ T cell populations. Int Immunol 1995;7:1157-61.
17. Koseki H, Imai K, Ichikawa T, Hayata I, Taniguchi M. Predominant use of a particular α-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int Immunol 1989;1:557-64.
18. - α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCR α chain. J Exp Med 1993;178:1-16.
19. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
20. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 1999;17:297-329.
21. Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, et al. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol 1997;159:1216-24.
22. α14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
23. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.
24. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
25. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900.
26. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
27. Behar SM, Cardell S. Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions. Semin Immunol 2000;12:551-60.
28. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol 2003;171:2142-53.
29. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated α-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003;171:4439-46.
30. 1 mice. J Immunol 2005;175:763-70.
31. Zeng D, Liu Y, Sidobre S, Kronenberg M, Straber S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 2003;112:1211-22.
32. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
33. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-20.
34. Dombrowicz D. Exploiting the innate immune system to control allergic asthma. Eur J Immunol 2005;35:2786-8.
35. Morishima Y, Ishii Y, Kimura T, Shibuya A, Shibuya K, Hegab AE, et al. Suppression of eosinophilic airway inflammation by treatment with α-galactosylceramide. Eur J Immunol 2005;35:2803-14.
36. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001;194:1789-99.
37. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 2006;34:49-66.
38. Singh AK, Yang JQ, Parekh VV, Wei J, Wang CR, Joyce S, et al. The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 2005;35:1143-54.
39. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+,BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001;44:1127-38.
40. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-8.
41. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, et al. Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001;28:275-83.
42. Zeng D, Lee MK, Tung J, Brendolan A, Straber S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 2000;164:5000-4.
43. Hahn BH, Singh RR. Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 299-355.
44. Yue SC, Shaulov A, Wang R, Balk SP, Exley MA. CD1d ligation on human monocytes directly signals rapid NF-κB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A 2005;102:11811-6.
45. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997;6:469-77.
46. Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003;170:4818-25.
47. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan BA, Khurana A, et al. A modified α-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods 2006;312:34-9.
48. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody vs. T cell-mediated autoimmunity. J Exp Med 1996;183:1613-21.
49. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005;14:189-91.
50. Park SH, Weiss A, Benlagha K, Kyin T, Teyton L, Bendelac A. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J Exp Med 2001;193:893-904.
51. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramere. J Exp Med 2000;192:741-54.
52. Esteban LM, Tsoutsman T, Jordan MA, Roach D, Poulton LD, Brooks A, et al. Genetic control of NKT cell numbers maps to major diabetes and lupus loci. J Immunol 2003;171:2873-8.
53. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993;177:155-64.
54. lpr mice: an example of disease regulation at the organ level. J Immunol 2001;167:2985-90.
55. Yang JQ, Chun T, Liu H, Hong S, Bui H, Van Kaer L, et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004;34:1723-32.
56. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H, Reeves WH. Interferon-γ required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001;60:2173-80.
57. Santiago ML, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. J Exp Med 1997;185:65-70.
58. Singh RR, Yang JQ. NKT cells suppress autoreactive B cells [abstract]. J Immunol 2006;176 Suppl:S151.
59. Singh RR, Wen X, Yang JQ. iNKT cells suppress autoreactive B cells in a contact-dependent manner. Submitted for publication.
60. Capone M, Troesch M, Eberl G, Hausmann B, Palmer E, MacDonald HR. A critical role for the T cell receptor α-chain connecting peptide domain in positive selection of CD1-independent NKT cells. Eur J Immunol 2001;31:1867-75.
61. Dang Y, Heyborne KD. Cutting edge: regulation of uterine NKT cells by a fetal class I molecule other than CD1. J Immunol 2001;166:3641-4.
62. 2-microglobulin-deficient mice have hybrid phenotype and function of NK and T cells. J Immunol 2004;172:6115-22.
63. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 2006;25:441-54.